Primevera Therapeutics

Primevera Therapeutics is a clinical-stage biotechnology company developing selective MMP-12 inhibitors to treat diseases driven by chronic inflammation, tissue remodeling, and fibrosis, including sarcoidosis, asthma, COPD, inflammatory bowel disease, interstitial lung diseases, and neurologic disorders.